Scarica l'app Stockscreener
0.459
12.89%
0.0524
Dopo l'orario di chiusura:
.43
-0.029
-6.32%
Precedente Chiudi:
$0.4066
Aprire:
$0.403
Volume 24 ore:
821.80K
Relative Volume:
0.23
Capitalizzazione di mercato:
$13.65M
Reddito:
-
Utile/perdita netta:
$-27.04M
Rapporto P/E:
-0.2325
EPS:
-1.9743
Flusso di cassa netto:
$-17.53M
1 W Prestazione:
-6.13%
1M Prestazione:
-70.00%
6M Prestazione:
-80.17%
1 anno Prestazione:
-87.66%
Intervallo 1D:
$0.395
$0.4626
Intervallo di 1 settimana:
$0.3914
$0.5136
Portata 52W:
$0.37
$8.94
Medicus Pharma Ltd Stock (MDCX) Company Profile
Nome
Medicus Pharma Ltd
Settore
Industria
Telefono
610-540-7515
Indirizzo
300 CONSHOHOCKEN STATE RD., W. CONSHOHOCKEN
Compare MDCX vs LLY, JNJ, ABBV, AZN, MRK
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MDCX
Medicus Pharma Ltd
|
0.459 | 12.09M | 0 | -27.04M | -17.53M | -1.9743 |
LLY
Lilly Eli Co
|
919.77 | 792.08B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
244.44 | 584.06B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
217.49 | 376.96B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
197.22 | 300.68B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
120.29 | 291.99B | 64.93B | 18.26B | 12.36B | 7.2751 |
Medicus Pharma Ltd Borsa (MDCX) Ultime notizie
Ideas Watch: Is Medicus Pharma Ltd Equity Warrant likely to announce a buybackQuarterly Portfolio Summary & Accurate Trade Setup Notifications - baoquankhu1.vn
Medicus Pharma on Bloomberg World - Burlington Free Press
Small cap wrap: Namibia Critical Metals, Medicus Pharma, Greatland Resources... - Proactive financial news
Medicus Pharma’s SkinJect Phase 2 Data Validated by KOL With 80% Response Rate - TipRanks
Medicus Pharma’s SkinJect Data Earns KOL Validation With 80% Response in Phase 2 - TipRanks
D. Boral Capital cuts Medicus Pharma stock price target on dilution concerns - Investing.com Canada
Medicus Pharma highlights independent support for Phase 2 SkinJect results - Yahoo! Finance Canada
Medicus Pharma Ltd Reports KOL Validation of Skinject Phase 2 Data of 80% Overall Response Rate - marketscreener.com
Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate - Caledonian Record
Medicus study suggests 3 of 4 skin cancer lesions may clear without immediate surgery - Stock Titan
[EFFECT] Medicus Pharma Ltd. SEC Filing - stocktitan.net
Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony - Las Cruces Sun-News
Bull Bear: Is Medicus Pharma Ltd Equity Warrant stock forming a cup and handleMarket Risk Report & Momentum Based Trading Ideas - baoquankhu1.vn
Free cash flow per share of Medicus Pharma Ltd. – NASDAQ:MDCXW - TradingView
Medicus Pharma (MDCX): A Small-Cap Biotech Making Moves in 2026 - openPR.com
MDCXW Financials: Income Statement, Balance Sheet & Cash Flow - stocktitan.net
Medicus Pharma to host business update call featuring clinical investigator - MSN
Medicus Pharma reports 80% response rate in skin cancer study By Investing.com - Investing.com Canada
Medicus Pharma Highlights Strong SkinJect Phase 2 Results and AI-Driven Development Plan - TipRanks
Medicus Pharma advances SkinJect, Teverelix programs, eyes catalyst-rich 2026 - Yahoo Finance
Medicus Pharma reports 80% response rate in skin cancer study - Investing.com
Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan - The Manila Times
Three in four lesions cleared in Medicus skin cancer study at Day 57 - stocktitan.net
Momentum Shift: Is Medicus Pharma Ltd Equity Warrant a potential multi baggerPortfolio Update Report & Stock Market Timing Techniques - baoquankhu1.vn
Medicus Biosciences—Biotech Company Focused on Innovative Microneedle Technology and Global Patent Portfolio - Minichart
Medicus Pharma Advances SkinJect and Teverelix Pipelines, Adds AI to Clinical Strategy - TipRanks
MDCX SEC FilingsMedicus Pharma Ltd 10-K, 10-Q, 8-K Forms - Stock Titan
Medicus Pharma Ltd reports results for the quarter ended December 31Earnings Summary - TradingView
Medicus Pharma (MDCX) registers 7.5M shares; Phase 2 D‑MNA topline noted - Stock Titan
Medicus Pharma (NASDAQ: MDCX) registers 3.245M common shares from warrants - Stock Titan
Medicus Pharma (MDCX) 1.12M shares issuable on warrants — prospectus supplement - Stock Titan
Medicus Pharma (MDCX) registers 2.26M shares tied to public warrants - Stock Titan
1.397M resale shares registered as Medicus Pharma (NASDAQ: MDCX) shifts S-1 to S-3 - stocktitan.net
[POS AM] Medicus Pharma Ltd. SEC Filing - stocktitan.net
Medicus Pharma (MDCX) files prospectus supplement registering 1.397M shares - Stock Titan
Medicus Pharma (NASDAQ: MDCX) outlines SkinJect and Teverelix clinical plans - stocktitan.net
Medicus Pharma Reports Full-Year 2025 Financial Results and Provides Corporate Update - ACCESS Newswire
Biotech says 3 in 4 patients may avoid immediate skin cancer surgery - stocktitan.net
Medicus Pharma 2025 10-K: Net loss $35.4M, EPS $(2.74) - TradingView
MDCX Stock Price, Quote & Chart | MEDICUS PHARMA LTD (NASDAQ:MDCX) - ChartMill
Medicus Pharma to Host Business Update Call Featuring Clinical Investigator - MyChesCo
Medicus Pharma Ltd.Common Stock (NQ: MDCX - The Chronicle-Journal
Medicus Pharma reports phase 2 results for basal cell carcinoma therapy - MSN
Medicus Pharma stock swings after skin cancer treatment results - msn.com
EBITDA per share of Medicus Pharma Ltd. – NASDAQ:MDCXW - TradingView
Tangible book value per share of Medicus Pharma Ltd. – NASDAQ:MDCXW - TradingView
Book value per share of Medicus Pharma Ltd. – NASDAQ:MDCXW - TradingView
Working capital per share of Medicus Pharma Ltd. – NASDAQ:MDCXW - TradingView
Revenue per share of Medicus Pharma Ltd. – NASDAQ:MDCXW - TradingView
Whats next for Medicus Pharma Ltd Equity Warrant stock2026 Technical Overview & Precise Swing Trade Alerts - baoquankhu1.vn
Medicus reports phase 2 results for SkinJect basal cell carcinoma study - MSN
Medicus Pharma Ltd Azioni (MDCX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Medicus Pharma Ltd Azioni (MDCX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| VELOCITY FUND PARTNERS, LP | 10% Owner |
May 20 '25 |
Sale |
7.72 |
75,000 |
578,940 |
3,248,741 |
1.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):